Publications by authors named "Margarita Romeo-Marin"
Article Synopsis
- The SORAYA trial investigated the efficacy of mirvetuximab soravtansine-gynx in patients with FRα-high platinum-resistant ovarian cancer, achieving a primary endpoint with an objective response rate of 32.4%.
- With a median overall survival of 15.0 months, those with fewer previous therapies had better outcomes (18.7 months for one to two lines vs. 11.6 months for three lines).
- Response rates varied by treatment history, with a higher objective response rate noted in patients receiving mirvetuximab as their first treatment in the platinum-resistant setting (34.8%) compared to those who had prior therapies (28.2%).
Article Synopsis
- The ORZORA trial tested the effectiveness and safety of olaparib as a maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer who have BRCA mutations or non-BRCA homologous recombination repair mutations after prior chemotherapy.
- The study involved 177 patients who received olaparib, with a median follow-up showing progression-free survival rates varying between 16.4 and 19.3 months depending on mutation type.
- Results indicated that most patients with BRCA mutations either improved or maintained their quality of life, and the safety profile of olaparib was consistent with expectations, reinforcing its use for these patients.
Article Synopsis
- Mirvetuximab soravtansine (MIRV) is a new treatment targeting folate receptor α (FRα) for patients with platinum-resistant epithelial ovarian cancer (PROC), evaluated in the SORAYA study.
- The study involved 106 patients, primarily with advanced treatment histories, finding an objective response rate (ORR) of 32.4% with a median response duration of 6.9 months.
- While MIRV showed promising efficacy, common side effects included blurred vision, keratopathy, and nausea, which sometimes led to treatment modifications for nearly half of the patients.
Objective: Progression-free survival (PFS) is an important early efficacy endpoint in ovarian cancer (OC) and its relevance to patients should be assessed. PRIMA, a phase III trial, assessed niraparib in patients with OC; this post hoc analysis examined the relationship between disease progression in OC and health-related quality of life (HRQoL).
Methods: The PRIMA trial randomized patients with advanced OC responsive to first-line platinum-based chemotherapy to once daily maintenance oral niraparib or placebo.
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Int J Gynecol Cancer
July 2019
Background: Bevacizumab is an approved treatment after primary debulking surgery for ovarian cancer. However, there is limited information on bevacizumab added to neoadjuvant chemotherapy before interval debulking surgery.
Objective: To evaluate neoadjuvant bevacizumab in a randomized phase II trial.